1.877.criver.1 | www.criver.com | askcharlesriver@crl.com

DISCOVERY

BECAUSE WE BELIEVE THERE IS A CURE. We define drug discovery as the ability to identify, evaluate and develop successful new therapeutics that treat human disease and improve our quality of life.

Outsourcing in the preclinical drug development space is often driven by the need for specialized in vitro and in vivo models, as well as a preference for organizations that offer streamlined discovery services from target identification to safety and toxicity studies. Because we believe in the work our clients’ mission, we are driven to deliver the science and technologies that can best support their quest for a cure. Through our continued investments, we are unequaled in our ability to provide fully integrated services that allow our partners to discover and develop novel therapeutics in an efficient and cost-effective manner.

Charles River is the preclinical CRO partner of choice with the therapeutic expertise, expansive capabilities, operational excellence and customer-centric flexibility that clients need to optimize their drug development programs. We are proud to have supported the development of more than half of the new molecular entities approved by the FDA in the last 2 years, a fact which gives clients the confidence to partner with us. Hailing from both major pharma and biotech companies, drug developers around the globe continue to choose Charles River as their trusted companion on the journey to market.

WHY DO WE DO DISCOVERY?

02

Working closely with our partners, we help them make the critical go/no-go decisions that move drugs through the development process from the lab to the clinic, and ultimately to the patients who need them.

Drug discovery is not a simple left to right progression. The path from target identification to clinical candidacy is marked by continuous iterations across the process. This reality demands a partner who can guide clients through repetitions and refinements at each stage. We combine industry-proven experience and broad capabilities in chemistry, biology and pharmacology to optimize our clients’ progress along their compound’s unique drug discovery path.

WHAT WE DO THE DRUG DISCOVERY PROCESS

‘END TO END’ INTEGRATED DRUG DISCOVERY

In Vitro Capabilities Therapeutic Areas

• Understanding target biology

• Complex biology: primary/patient derived

• Hit finding & compound libraries

• Crystallography, biophysics

• In vitro safety assessment

• Chemistry: medicinal, synthetic, process

• ADME/PK

• Pharmaceutics

• Oncology

• CNS/pain

• Inflammation & Immunology

• CV & Metabolic

• Respiratory

• Rare & neglected disease

• Ocular

• Other

CHEMISTRY

BIOLOGY

PHARMACOLOGY

ONCOLOGY CNS

RESPIRATORYRARE DISEASE

INFLAMM

ATIONCV/M

ETABOLISM

04

Innovation.Discovery from Charles River is unlike any other preclinical CRO— we are able to support dynamic drug discovery and development every step of the way. Our integrated multidisciplinary team is skilled across a wide range of disease areas and has access to the most advanced science and latest technologies through our continued investment in instrumentation and education. Our scientists publish and collaborate with colleagues in their fields, and share their work with the global community.

HOW ARE WE DIFFERENT ?

Committed to advancing research, we forge the academic partnerships that fuel innovation and work to support our partners’ search for critical funding.

Efficiency.Always on the cutting edge, our facilities feature state-of-the-art equipment, much of which is highly customized and often superior to commercially available options. Moreover, the streamlined nature of our extensive capabilities creates greater cost efficiencies for more traditional services. For example, our translational imaging capabilities provide us with more information than traditional non-invasive imaging. Richer, more relevant data optimizes the use of resources and improves study outcomes.

Collaboration.With discovery specialists located around the globe, we partner with organizations large and small across pharma, biotech and academia, and currently support over a hundred integrated drug discovery programs. From stand-alone studies to complete programs, we offer flexible business models tailored to suit the unique needs of our clients.

06

650+ SCIENTISTS WITH: More than 300 patents at Charles River Thousands of peer-reviewed publications

OUR TEAMS CONTRIBUTE TO: Over 1000 in vivo studies per yearOver 100 drug discovery programs per year

Account Managers/Specialists

Client Services

Study Directors

Program Managers

Scientists

Site Heads & Department

Heads

Research Associates & Technicians

It’s our job to design molecules that have the best chances of going all the way through that

pipeline to the clinic.

A lot of what we do is new science…you can’t read it in the literature and we are breaking new ground

all the time.

OUR CAPABILITIES START WITH OUR PEOPLE

08

ClientYOUR CHARLES RIVER SUPPORT TEAM

Disease Area

No. of Candidates

Preclinical Phase I Phase IIa Phase IIb Phase III Registration

Inflammation13

CHEMOKINE, INTEGRIN, GPCR, CYTOKINE, KINASE, ENZYME

Respiratory 24GPCR, PROTEASE NHR, KINASE

CNS 6GPCR, NHR

Metabolic disease 4

ENZYME, KINASE, PROTEASE

Oncology 12ENZYME, KINASE, PPI

Anti-bacterial1

UNKNOWN

Anti-viral1

PROTEASE

Cardiovascular 2ION CHANNEL

Secretory gastrointestinal 1

ION CHANNEL

27% CANDIDATES HAVE PROGRESSED TO CLINICAL POC OR BEYOND

Significantly better than the industry standard (12-24%)

Additional 11 being progressed towards clinical PoC

DISCOVERY FROM CHARLES RIVER BY THE NUMBERS

>60 development candidates in the past 15 years

At least 5 candidates per year for the last decade

29 clinical candidates

More than 3,000 studies performed per year

10